What Health Catalyst (HCAT) Said on Its Q3 Earnings Call

Health Catalyst (HCAT) reported Q3 revenue of $56.3M ($40.7M tech, $15.6M services), with adjusted gross margin falling to 44.3% from 52.6% YoY. Adjusted net loss was $0.03 per share. The company expects a Q4 adjusted EBITDA loss of $1.8M-$1.3M, citing Vitalware's removal and higher medical claims. HCAT ended Q3 with $79M in cash and no debt.

Original reporting
Published Nov 6, 2026, 6:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 6:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Health Catalyst (HCAT) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$HCATBearishMed
01

Why it matters

The earnings miss and guidance suggest near‑term downside risk, but cash reserves provide a cushion.

02

Market read

Earnings release is the primary catalyst for HCAT's near‑term price action.

03

What to watch

Potential cost savings from Project Nexus and the removal of Vitalware may improve future profitability.

Relevance 6/10Novelty 7/10Timing: today

Background

Health Catalyst reported Q3 technology and services revenue, margin compression, and a loss outlook for Q4.

Company-level read

Ticker impact

$HCATBearishMedium confidence
Context

Q3 earnings disclosed lower margins and a Q4 adjusted EBITDA loss guidance of $1.8M‑$1.3M.

Expected impact

downside pressure as investors price in margin compression and loss guidance

Evidence & confidence

The article provides the first report of Q3 results with declining margins and a loss outlook, which typically moves the stock lower.

Market effects

Highlights pressure on healthcare‑tech firms with high services cost structures.

US healthcare‑tech segment may see modest pullback.

Limited to investors tracking US health‑data analytics stocks.

Counterpoint

If the cash position remains strong and the loss is one‑time, the stock could be undervalued.

Key entities

  • Health Catalyst, Inc.

    Healthcare technology firm providing data and analytics solutions.

Related articles

$HCATMed

Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.